Stem cells are often described as the body's master cells. Healthy stem cells can restore the blood system after cancer ...

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

Detailed price information for Medexus Pharmaceuticals Inc (MDP-T) from The Globe and Mail including charting and trades.

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100: Redwood City, California Tuesday, April 15, 2025, 18:00 Hrs [IST] Exicure, Inc., an early-stage bio ...

At just 27 years old, Moonii was a thriving entrepreneur, running multiple successful businesses and even winning prestigious ...

A YOUNG doctor was told she has cancer while on shift in A&E just one hour after having a blood test for suspected glandular ...

Alice Bolton, a 28-year-old doctor was diagnosed with acute myeloid leukaemia (AML), an aggressive form of blood cancer, in ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Discover how maintenance therapy improves transplant outcomes for high-risk AML patients, with key insights from EBMT 2025.